晚期恶性肿瘤中免疫耐受的逆转:通过阻断干细胞因子功能调节髓源性抑制细胞的发育。
Reversion of immune tolerance in advanced malignancy: modulation of myeloid-derived suppressor cell development by blockade of stem-cell factor function.
作者信息
Pan Ping-Ying, Wang George X, Yin Bingjiao, Ozao Junko, Ku Teresa, Divino Celia M, Chen Shu-Hsia
机构信息
Department of Gene and Cell Medicine, Mount Sinai School of Medicine, New York, NY 10029, USA.
出版信息
Blood. 2008 Jan 1;111(1):219-28. doi: 10.1182/blood-2007-04-086835. Epub 2007 Sep 20.
Tumor growth induced a significant increase of myeloid-derived suppressor cells (MDSCs) in the tumor-bearing host. In our previous study, we showed that MDSCs induced tumor-specific T-cell tolerance and the development of T regulatory cells (Tregs). Tumor-derived factors have been implicated in the accumulation of MDSCs. We hypothesize that reduction of MDSC accumulation in tumor-bearing hosts, through the blockade of tumor factors, can prevent T-cell anergy and Treg development and thereby improve immune therapy for the treatment of advanced tumors. Several tumor-derived factors were identified by gene array analysis. Among the candidate factors, stem- cell factor (SCF) is expressed by various human and murine carcinomas and was selected for further study. Mice bearing tumor cells with SCF siRNA knockdown exhibited significantly reduced MDSC expansion and restored proliferative responses of tumor-infiltrating T cells. More importantly, blockade of SCF receptor (ckit)-SCF interaction by anti-ckit prevented tumor-specific T-cell anergy, Treg development, and tumor angiogenesis. Furthermore, the prevention of MDSC accumulation in conjunction with immune activation therapy showed synergistic therapeutic effect when treating mice bearing large tumors. This information supports the notion that modulation of MDSC development may be required to achieve effective immune-enhancing therapy for the treatment of advanced tumors.
肿瘤生长导致荷瘤宿主中髓源性抑制细胞(MDSCs)显著增加。在我们之前的研究中,我们表明MDSCs可诱导肿瘤特异性T细胞耐受和调节性T细胞(Tregs)的产生。肿瘤衍生因子与MDSCs的积累有关。我们假设,通过阻断肿瘤因子来减少荷瘤宿主中MDSCs的积累,可以防止T细胞无反应性和Tregs的产生,从而改善晚期肿瘤治疗的免疫疗法。通过基因阵列分析鉴定了几种肿瘤衍生因子。在候选因子中,干细胞因子(SCF)在多种人类和小鼠癌症中表达,并被选择进行进一步研究。携带SCF siRNA敲低的肿瘤细胞的小鼠表现出MDSC扩增显著减少,肿瘤浸润T细胞的增殖反应恢复。更重要的是,抗ckit阻断SCF受体(ckit)-SCF相互作用可防止肿瘤特异性T细胞无反应性、Tregs产生和肿瘤血管生成。此外,在治疗携带大肿瘤的小鼠时,防止MDSC积累与免疫激活疗法联合显示出协同治疗效果。这一信息支持了这样一种观点,即可能需要调节MDSC的发育才能实现有效的免疫增强疗法来治疗晚期肿瘤。